StockData
Medtronic plc logo

Medtronic plc (MDT) stock

MDTNYSEElectromedical & Electrotherapeutic ApparatusFiscal year ends April 24
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 3, 2026Score 19/303% below fair value
$96.54−0.57 (-0.59%)

Close on Oct 30, 2026Market cap $123.49BP/E 23.7Yield 2.94%

Earnings

Medtronic's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Nov 17, 2026
Q2 FY2027 · estimated, before the open
Revenue, Q1 FY2027
$9.76B
+13.7% on a year earlier
non-GAAP diluted EPS, Q1 FY2027
$1.45
$1.26 a year earlier
Latest guidance
Raised
Sep 1, 2026 · 2 items

Quarterly results

Revenue and earnings per share from each of Medtronic's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q2 FY2027ended Oct 24, 2026Nov 17, 2026Expected–––––
Q1 FY2027ended Jul 31, 2026Sep 1, 2026before the open$9.76B+13.7%$1.14$1.45Release
Q4 FY2026ended Apr 24, 2026Jun 3, 2026before the open$9.81B+10.2%$0.96$1.55Release
Q3 FY2026ended Jan 23, 2026Feb 17, 2026before the open$9.00B+8.5%$0.89$1.36Release
Q2 FY2026ended Oct 24, 2025Nov 18, 2025before the open$8.96B+6.6%$1.07$1.36Release
Q1 FY2026ended Jul 25, 2025Aug 19, 2025before the open$8.58B+8.4%$0.81$1.26Release
Q4 FY2025ended Apr 25, 2025May 21, 2025before the open$8.90B+3.6%$0.82$1.62Release
Q3 FY2025ended Jan 24, 2025Feb 18, 2025before the open$8.29B+2.5%$1.01$1.39Release
Q2 FY2025ended Oct 25, 2024Nov 19, 2024before the open$8.40B+5.2%$0.99$1.26Release
Q1 FY2025ended Jul 26, 2024Aug 20, 2024before the open$7.92B+2.8%$0.80$1.23Release
Q4 FY2024ended Apr 26, 2024May 23, 2024before the open$8.59B+0.5%$0.49$1.46Release
Q3 FY2024ended Jan 26, 2024Feb 20, 2024before the open$8.09B+4.7%$0.99$1.30Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Medtronic's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
organic revenue growthnon-GAAPFY2027+7.25% – +7.75%+6.75% – +7.25%RaisedSep 1, 2026
diluted non-GAAP EPSnon-GAAPFY2027$5.94 – $6.00$5.90 – $6.00RaisedSep 1, 2026
diluted non-GAAP EPS growthnon-GAAPFY2027+6.7% – +8.5%–NewJun 3, 2026

Guidance vs results

The last range Medtronic gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2026diluted non-GAAP EPS$5.62 – $5.66$5.53Σ4QBelow range
FY2026Revenue growth+6.5% – +6.8%+8.46%Σ4QAbove range
FY2025diluted non-GAAP EPS$5.44 – $5.50$5.50Σ4QWithin range
FY2025Revenue growth+3.4% – +3.8%+3.54%Σ4QWithin range
Q4 FY2022non-GAAP EPS$1.56 – $1.58$1.52Below range

Guidance history

Every forecast Medtronic put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Sep 1, 2026diluted non-GAAP EPSFY2027$5.94 – $6.00Raised
Sep 1, 2026organic revenue growthFY2027+7.25% – +7.75%Raised
Jun 3, 2026diluted non-GAAP EPSFY2027$5.90 – $6.00New
Jun 3, 2026diluted non-GAAP EPS growthFY2027+6.7% – +8.5%New
Jun 3, 2026organic revenue growthFY2027+6.75% – +7.25%New
Feb 17, 2026diluted non-GAAP EPSFY2026$5.62 – $5.66Reaffirmed
Feb 17, 2026organic revenue growthFY2026+5.5%Reaffirmed
Nov 18, 2025diluted non-GAAP EPSFY2026$5.62 – $5.66Raised
Nov 18, 2025organic revenue growthFY2026+5.5%Raised
Aug 19, 2025underlying FY26 diluted non-GAAP EPS growthFY2026+4.5%Raised
Aug 19, 2025revenue growth on a reported basisFY2026+6.5% – +6.8%Raised
Aug 19, 2025organic revenue growthFY2026+5%Reaffirmed
May 21, 2025diluted non-GAAP EPS growthFY2026+4%New
May 21, 2025diluted non-GAAP EPSFY2026$5.50 – $5.60New
May 21, 2025revenue growth on a reported basisFY2026+4.8% – +5.1%New
May 21, 2025organic revenue growthFY2026+5%New
Feb 18, 2025diluted non-GAAP EPS growthFY2025+4.6% – +5.8%Reaffirmed
Feb 18, 2025diluted non-GAAP EPSFY2025$5.44 – $5.50Reaffirmed
Feb 18, 2025revenue growthFY2025+3.4% – +3.8%New
Feb 18, 2025organic revenue growthFY2025+4.75% – +5%Raised

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Medtronic filed with the SEC as exhibits to Form 8-K or 6-K

  1. Medtronic Completes Separation of MiniMed Group, Inc.
    Update
  2. Medtronic reports first quarter fiscal 2027 results; delivers broad-based portfolio performance and raises fiscal 2027 guidance
    Results
  3. Medtronic reports fourth quarter and full year fiscal 2026 results; delivers highest annual revenue growth in 10 years
    Results
  4. Medtronic statement on unauthorized system access
    Update
  5. Medtronic reports strong third quarter
    Results
  6. Medtronic reports strong second quarter
    Results
  7. 11 th quarter in a row of mid-single digit organic revenue growth;
    Results
  8. Medtronic announces Board appointments and shareholder value creation initiatives to advance strategic priorities
    Results
  9. Medtronic reports strong finish to its fiscal year with its fourth quarter financial results;
    Results
  10. Medtronic announces intent to separate Diabetes business
    Results
  11. Delivering durable revenue growth with strong earnings power; strength in Pulsed Field Ablation, Pacing, Structural Heart, Diabetes, and Neuromodulation
    Results
  12. Delivering on commitments, executing ahead of expectations, and raising guidance
    Results
  13. Quarterly results release
    Results
  14. Medtronic announces departure of Karen Parkhill, Chief Financial Officer
    Update
  15. Medtronic reports full year and fourth quarter
    Results